Drugs / NBI-1070770
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06267846 | Mar 2024 → Jul 2025 | major depressive disorder | Neurocrine Biosciences | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-04-03 | Neurocrine Biosciences | Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder gcs-web.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NBI-1070770 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06267846 ↗ |
| Route | Oral | “Suspension for oral administration” NCT06267846 ↗ |